Betacyclodextrin
Score impact
0.00
points/product
Description
Betacyclodextrin (E459) is a food additive classified as a stabilizer, although it also acts as an encapsulant and absorption enhancer. It is a cyclic oligosaccharide composed of seven glucose units linked by α-1,4 bonds, forming a truncated cone structure with a hydrophobic internal cavity and a hydrophilic external surface. This unique structure allows it to form inclusion complexes with lipophilic molecules, improving their solubility, stability, and bioavailability.
Industrially, betacyclodextrin is obtained by the action of the enzyme cyclodextrin glucanotransferase (CGTase) on pre-liquefied starch. The enzyme, produced by microorganisms such as Bacillus macerans, converts starch into a mixture of cyclodextrins (α, β, and γ), which are then separated and purified by chromatographic or selective precipitation techniques. The final product is a white, crystalline, odorless powder with a slightly sweet taste.
Betacyclodextrin was approved as a food additive in the European Union in 1998, following evaluation by the Scientific Committee on Food (SCF). Subsequently, the European Food Safety Authority (EFSA) has re-evaluated its safety on several occasions, most recently in 2016, establishing an Acceptable Daily Intake (ADI) of 5 mg/kg body weight per day. The World Health Organization (WHO) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) have also evaluated betacyclodextrin, assigning an ADI of 0-5 mg/kg bw/day. Both agencies agree that the additive is safe at authorized use levels.
Regarding its safety, EFSA concludes that betacyclodextrin is not genotoxic or carcinogenic, and chronic toxicity studies showed no relevant adverse effects. The main effects observed in animals at high doses were diarrhea and changes in intestinal microbiota, but these are not considered relevant for human exposure within established limits. Betacyclodextrin is partially metabolized in the colon by microbiota, producing short-chain fatty acids, and the remainder is excreted unchanged in feces.
In food labeling, betacyclodextrin must be listed as "betacyclodextrin" or "E459" in the ingredient list. No special warning is required. Globally, it is considered a safe and well-tolerated additive with a favorable toxicological profile.
Betacyclodextrin (E459) is used in various food categories as a stabilizer, encapsulant, and absorption enhancer. According to Regulation (EC) No 1333/2008, it is authorized in the European Union for use in food supplements, foods for special medical purposes, and as a carrier for flavors and other ingredients. In Spain, it is commonly found in products such as energy drinks, vitamin supplements, chewing gum, sugar-free candies, and fine bakery products. It is also used in the encapsulation of essential oils, fat-soluble vitamins (A, D, E, K), and natural colors to improve their stability and solubility.
Maximum use levels vary by category: in food supplements, the maximum dose is 500 mg/kg (0.05%) in the ready-to-eat product; in foods for special medical purposes, up to 50,000 mg/kg (5%) in the ready-to-eat product; and as a flavor carrier, quantum satis (sufficient amount to achieve the desired effect). In comparison, the US FDA classifies betacyclodextrin as Generally Recognized as Safe (GRAS) for similar uses, with an estimated daily intake of up to 2 g/person/day. Japan also approves it as a food additive, with limits similar to European ones. The versatility of betacyclodextrin makes it especially useful in the food industry for improving texture, preventing phase separation, and protecting sensitive ingredients.
Documented side effects of betacyclodextrin (E459) are rare and generally mild, mainly related to very high doses. Human studies have shown that intakes above 10 g/day can cause gastrointestinal discomfort such as flatulence, abdominal distension, and osmotic diarrhea, due to its partial fermentation by colonic microbiota. No systemic toxic, genotoxic, or carcinogenic effects have been reported in studies conducted by EFSA and JECFA. The ADI of 5 mg/kg bw/day (equivalent to 350 mg/day for a 70 kg adult) provides a wide safety margin, as estimated dietary intake is much lower.
The biological mechanism of these gastrointestinal effects is that betacyclodextrin is not digested in the small intestine but reaches the colon, where it is fermented by bacteria, producing gases and short-chain fatty acids. In people with irritable bowel syndrome or digestive sensitivity, these effects may be more noticeable, although there are no specific contraindications. No significant interactions with medications have been described, although theoretically it could reduce the absorption of lipophilic drugs if ingested simultaneously, due to its ability to form inclusion complexes. However, in practice, the amounts used in foods are too low to cause this effect.
EFSA and WHO conclude that betacyclodextrin is safe for the general population at authorized use levels and does not require special warnings on labeling. Sensitive populations, such as children or pregnant women, have no additional risks, as estimated exposure is well below the ADI. In summary, the safety profile of betacyclodextrin is excellent, and adverse effects are only observed at doses far above food use levels.
- Beta-cyclodextrin
- β-cyclodextrin
- Cyclomaltoheptaose
- Cycloheptaamylose
- BCD
- Betadex
- Cyclic heptaamylose
- Beta-cyclodextrin
- Cyclodextrin beta
Classification:
Statistics
15
total views
Something wrong?
If you notice incorrect or incomplete information, help us improve the platform.